Sunshine Biopharma (SBFM) Short term Debt (2018 - 2019)

Sunshine Biopharma's (SBFM) quarterly Short term Debt came in at $27541.0 in Q3 2019, down 1.18% on a QoQ basis from $27869.0 in Q2 2019.

Sunshine Biopharma (SBFM) Short term Debt (2018 - 2019) Analysis & Trends

Sunshine Biopharma (SBFM) has 2 years of Short term Debt data on file, last reported at $27541.0 in Q3 2019.

Quarterly Short term Debt changed N/A year-over-year to $27541.0 in Q3 2019, while the trailing twelve-month figure through Sep 2019 was $27541.0 (changed N/A YoY) and the FY2018 annual result came in at $20871.0, changed N/A from the prior year.
Short term Debt slipped to $27541.0 in Q3 2019, from $27869.0 in the prior quarter.
In the past five years, Short term Debt ranged from a high of $59558.0 in Q1 2019 to a low of $20871.0 in Q4 2018.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Haleon	43.83 Bn	42.86 Bn	-
2	Teva Pharmaceutical Industries	42.87 Bn	39.22 Bn	2.15 Bn
3	Zoetis	31.41 Bn	29.73 Bn	1.05 Bn
4	Takeda Pharmaceutical	28.55 Bn	22.75 Bn	5.10 Bn
5	United Therapeutics	22.08 Bn	19.42 Bn	683.80 Mn
6	Viatris	18.73 Bn	17.84 Bn	1.46 Bn
7	Neurocrine Biosciences	15.44 Bn	15.05 Bn	935.80 Mn
8	Elanco Animal Health	11.75 Bn	11.22 Bn	798.00 Mn
9	Dr Reddys Laboratories	10.11 Bn	9.94 Bn	-
10	Sunshine Biopharma	1.58 Mn	-12.17 Mn	2.43 Mn

Download Data